A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Patients chronically infected with Hepatitis C * Subjects who received a liver transplant, have chronic hepatitis C virus (HCV) recurrence and advanced fibrosis (Metavir F3-F4) or fibrosing cholestatic hepatitis * Subjects with decompensated cirrhosis defined by Child-Pugh Class C Exclusion Criteria: * Patients who are \<18 years old * Clinical or pathologic evidence of acute ongoing liver graft rejection * Creatinine clearance (CrCl) ≤30 mL/min (as estimated by Cockcroft and Gault formula) * Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF) * Patients who are pregnant or Women of Child Bearing Potential who are not using required contraception